New Delhi: Covid cases once again jump in India after seeing a down trend as on Thursday around 54,069 more people were tested positive, as per the Union health ministry. The positivity rate is currently at 2.09% and the weekly positivity rate at 3.04%.
On Wednesday, the number stood at 50,848 but with the addition of new infections, the cumulative caseload has increased to 3,00,82,778.
However, death due to Covid complexities have decreased in the period with 1,321 more people succumbing to the disease. The death toll due to Covid-19 now stands at 3,91,981.
On the brighter side, recoveries have outnumbered fresh infections for the 42nd day as 68,885 were discharged between Wednesday and Thursday. While the total number of discharges have reached 2,90,63,740, the recovery rate has improved to 96.61%.
As a result, there are 6,27,057 active cases left in the country currently. The active tally has dipped by 16,137 in the last 24 hours.
Notably, India has tested 39,78,32,667 samples for Covid-19 until now, according to the India Council of Medical Research (ICMR).
Out of these, 18,59,469 samples were tested on Wednesday. As many as 19,01,056 tests were conducted during the previous 24-hour period.
While, the country has so far administered 30,16,26,028 anti-Covid shots, said the health ministry. As many as 64,89,599 from these were given in the last 24 hours.
India’s Covid-19 vaccine coverage has also breached the record breaking 30 crore mark on Wednesday.
Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Rajasthan, Tamil Nadu, Telangana, Odisha, Uttar Pradesh and West Bengal have administered at least one dose of the vaccine to more than 10 lakh beneficiaries of the 18-44 age group.
Vaccine efficacy on Delta Plus
Following the detection of the new ‘Delta Plus’ Covid variant, the ICMR and the National Institute of Virology (NIV) have decided to conduct a study to see if the strain of coronavirus can be neutralised by the existing vaccines in India.
The study is likely to involve Covaxin and Covishield vaccines.
“As per earlier data concerning Delta variant, neutralization was happening with the existing vaccines in India. Though neutralization has dropped, it’s enough to protect against Delta variant. Delta Plus should also behave (in a similar manner). We are working in this direction. We have isolated this variant and we are going to conduct a study soon. We will come back with the study,” said Dr Pragya Yadav, head of the NIV’s Maximum Containment Facility.
All Delta sub-lineages are treated as variants of concern (VOC) and properties of AY.1 are still being investigated. Delta Plus is also known as ‘AY.1’ variant or B.1.617.2.1.